在线观看av片丨亚洲 日本 欧美 中文幕丨国产免费午夜福利蜜芽无码丨国模福利视频丨色翁荡息又大又硬又粗又爽电影丨中国少妇裸体bbbbb丨国产99视频精品免视看9丨国产美女免费视频丨777国产盗摄视频000丨日批动态图丨青青青操丨久久久婷婷五月亚洲97色丨天堂成人丨国产成人亚洲影院在线播放丨欧美人与物videos另类xxxxx丨juliaann战黑人丨农村妇女毛片精品久久久丨黄色小视频网站免费丨老司机午夜精品视频丨日本免费在线观看视频丨特级少妇丨精品一卡二卡三卡丨狠狠色狠色综合曰曰丨亚洲精品三级丨999色综合

Home>About Livzon>Course
From 2020 to now
the enterprise develops rapidly and marches into the international market

  • Many industrial innovative products are coming soon

  • COVID-19 antibody detection reagent and many other products go out of China and enter the international market

2016-2019
the enterprise made the future layout based on its advantages

  • Expanded R&D team and introduced new R&D technology

  • Realized whole-line cold chain logistics for the first time nationwide

  • Completed the development and started the clinical test of many industry-leading project, such as irradiator, multiple, HIV, etc.

  • Be recognized as provincial level innovation and industrialization demonstration enterprise for several times

  • Established "Guangdong Postdoctoral Innovation Practice Base"

  • Be approved as a national “Post-Doctoral Research Center”

  • Established Suzhou R&D center

  • Moved into the new industrial park with a floor area of 23,000 m2

1998-2015
the enterprise restructured and started a new development way

  • Cooperated with many international IVD enterprises, such as Unipath, Fujirebro, Siemens, MP, etc.

  • The market share of AIDS confirmation reagents reached 80%, and the market share of drug concentration detection reached 50%,Many self-developed products occupied over 60% of the market share.Many products became reference methods for disease detection, such as MYCOII and TP.PA.

1989-1998
the enterprise was newly established by the Group

  • 1989, the first subsidiary of Livzon Pharmaceutical Group Inc.

  • Obtained pharmaceutical manufacturing license

  • Many products were successfully developed and marketed, including HBV, HIV, HCV ELISA reagents